Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1996 1
1997 1
1998 5
1999 1
2000 12
2001 13
2002 26
2003 30
2004 36
2005 31
2006 37
2007 29
2008 17
2009 18
2010 18
2011 18
2012 16
2013 14
2014 15
2015 11
2016 8
2017 4
2018 3
2019 3
2020 7
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

347 results
Results by year
Filters applied: . Clear all
Page 1
Tositumomab.
[No authors listed] [No authors listed] 2020 Apr 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012–. PMID: 31643663 Free Books & Documents. Review.
Tositumomab is the combination of a monoclonal antibody to CD20 and iodine-131 which is used to treat refractory, advanced non-Hodgkin lymphoma. ...However, tositumomab has potent immunosuppressive activity and is probably capable of causing reactivation of hepatiti
Tositumomab is the combination of a monoclonal antibody to CD20 and iodine-131 which is used to treat refractory, advanced non-Hodgki
I-131 tositumomab.
William BM, Bierman PJ. William BM, et al. Expert Opin Biol Ther. 2010 Aug;10(8):1271-8. doi: 10.1517/14712598.2010.504707. Expert Opin Biol Ther. 2010. PMID: 20590521 Review.
IMPORTANCE OF THE FIELD: Follicular lymphoma (FL) is a subgroup of B-cell Non-Hodgkin's lymphomas (NHL) that account for 15 - 30% of all lymphomas. I-131 tositumomab is a radiommunoconjugate of (131)I and the anti-CD20 monoclonal antibody tositumomab. ...This review …
IMPORTANCE OF THE FIELD: Follicular lymphoma (FL) is a subgroup of B-cell Non-Hodgkin's lymphomas (NHL) that account for 15 - 30% of all lym …
Tositumomab I 131.
[No authors listed] [No authors listed] 2020 Aug 17. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Drugs and Lactation Database (LactMed). 2006–. PMID: 29999771 Free Books & Documents. Review.
Information in this record refers to the use of tositumomab I 131 as a therapeutic agent. No information is available on the use of tositumomab I 131 during breastfeeding. ...Parents should limit close contact with their infants and small children after therapeutic …
Information in this record refers to the use of tositumomab I 131 as a therapeutic agent. No information is available on the use of …
(131)I-Tositumomab.
Cheng KT. Cheng KT. 2005 Oct 19 [updated 2008 Jun 2]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. Molecular Imaging and Contrast Agent Database (MICAD). 2004–2013. PMID: 20641455 Free Books & Documents. Review.
(131)I-Tositumomab ((131)I-B1 MAb) is a conjugation of (131)I with a murine anti-CD20 monoclonal antibody (MAb) that can be used for both imaging and therapy of lymphoid malignancies (1-8). ...Radiolabeled MAbs have been developed for both diagnosis and therapy of tumors ( …
(131)I-Tositumomab ((131)I-B1 MAb) is a conjugation of (131)I with a murine anti-CD20 monoclonal antibody (MAb) that can be used for …
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
Wahl RL. Wahl RL. J Nucl Med. 2005 Jan;46 Suppl 1:128S-40S. J Nucl Med. 2005. PMID: 15653661 Free article. Review.
Tositumomab and (131)I-tositumomab constitute a relatively new radioimmunotherapeutic regimen for patients with CD20+ follicular non-Hodgkin's lymphoma (NHL). ...Retreatment with tositumomab and (131)I-tositumomab and use of lower total-body radiation
Tositumomab and (131)I-tositumomab constitute a relatively new radioimmunotherapeutic regimen for patients with CD20+ follicul
Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
Friedberg JW, Fisher RI. Friedberg JW, et al. Expert Rev Anticancer Ther. 2004 Feb;4(1):18-26. doi: 10.1586/14737140.4.1.18. Expert Rev Anticancer Ther. 2004. PMID: 14748653 Review.
Tositumomab is linked covalently with iodine-131 to produce the radioimmunoconjugate iodine-131 tositumomab (Bexxar). ...The dose-limiting toxicity of iodine-131 tositumomab is bone marrow suppression and resulting cytopenias. Unlike chemotherapy, the majorit
Tositumomab is linked covalently with iodine-131 to produce the radioimmunoconjugate iodine-131 tositumomab (Bexxar). ...The d
131I tositumomab.
Culy CR, Lamb HM. Culy CR, et al. BioDrugs. 2000 Sep;14(3):195-202. doi: 10.2165/00063030-200014030-00005. BioDrugs. 2000. PMID: 18034570
black triangle (131)I tositumomab is a radiolabelled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen on normal and malignant B lymphocytes. It has antitumour activity as a result of emission of beta particles, and activation of antibody-dep …
black triangle (131)I tositumomab is a radiolabelled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen …
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
Zelenetz AD. Zelenetz AD. Semin Oncol. 2003 Apr;30(2 Suppl 4):22-30. doi: 10.1053/sonc.2003.23803. Semin Oncol. 2003. PMID: 12728404 Review.
Hematologic toxicity is the major dose-limiting toxicity associated with radioimmunotherapy; however, patient-specific dosimetry maintained hematologic toxicity within predictable, transient, and manageable limits in the phase II and phase III trials of tositumomab and iod …
Hematologic toxicity is the major dose-limiting toxicity associated with radioimmunotherapy; however, patient-specific dosimetry maintained …
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
Jacene H, Crandall J, Kasamon YL, Ambinder RF, Piantadosi S, Serena D, Kasecamp W, Wahl RL. Jacene H, et al. Mol Imaging Biol. 2017 Jun;19(3):429-436. doi: 10.1007/s11307-016-1019-9. Mol Imaging Biol. 2017. PMID: 27798787 Clinical Trial.
PURPOSE: To determine the maximum tolerated dose (MTD) of [(131)I]tositumomab in patients with refractory/recurrent Hodgkin lymphoma (HL) and to preliminarily determine if [(131)I]tositumomab has activity against HL and if positron emission tomography (PET) with 2-d …
PURPOSE: To determine the maximum tolerated dose (MTD) of [(131)I]tositumomab in patients with refractory/recurrent Hodgkin lymphoma …
Tositumomab and iodine I 131 tositumomab (Bexaar).
Srinivasan A, Mukherji SK. Srinivasan A, et al. AJNR Am J Neuroradiol. 2011 Apr;32(4):637-8. doi: 10.3174/ajnr.A2593. Epub 2011 Mar 24. AJNR Am J Neuroradiol. 2011. PMID: 21436340 Free article. Review.
Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. ...
Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen e
347 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page